On Friday, Liberty Global plc - Class A Ordinary Shares (NASDAQ:LBTYA)’s shares declined -3.24% to $50.41.
Liberty Global plc - Class A Ordinary Shares (LBTYA) declared financial and operating results1 for the three months ended March 31, 2015 (“Q1″).
Operating and financial highlights:
- Continued focus on high-value bundles offering superior broadband speeds, next-generation TV functionality, improved content and mobility
- Over 150,000 broadband additions and record quarter for Horizon TV growth in Q1
- Customer ARPU2raised 5%3 year-over-year on an FX-neutral basis
- Organic RGU4additions of 68,000 in Q1, principally influenced by higher video losses
- Underperformance in Germany, the Netherlands and Ireland drove majority of variance
- April RGU additions were back on track, with net adds running well ahead of April 2014
- Despite slow Q1, targeting over one million organic subscriber additions in 2015
- Revenue of $4.5 billion, reflecting rebased5growth of 3%, up from 2% in Q1’14
- Q1 price enhances in 12 markets lay foundation for balanced growth in 2015
- Improved year-over-year rebased revenue growth in 5 of 7 Western European markets
- Continued strong rebased revenue growth for mobile and B2B
- Operating Cash Flow6 of $2.1 billion, representing 1% rebased growth
- Growth negatively influenced by favorable nonrecurring items in Q1 2014
- Operating income of $558 million, a decrease of 4% year-over-year
- Free Cash Flow (“FCF”)7of $330 million, flat contrast to $336 million in Q1 2014
- Favorable capital market conditions improved already strong balance sheet
- Refinanced ~$6.5 billion in Q1 lowering fully-swapped borrowing cost to 5.4%
- Extended average tenor to nearly eight years, with over 90% due after 2019
- LiLAC tracking stock set to launch in early July
Liberty Global plc, together with its auxiliaries, provides video, broadband Internet, fixed-line telephony, and mobile services in Europe, Chile, Puerto Rico, and internationally.
Geron Corporation (NASDAQ:GERN)’s shares dropped -2.94% to $48.82.
Geron Corporation (GERN) stated financial results and recent events for the first quarter ended March 31, 2015.
First Quarter 2015 Results
For the first quarter of 2015, the company stated operating revenues of $537,000 and operating expenses of $10.0 million contrast to $474,000 and $9.2 million, respectively, for the comparable 2014 period. Operating expenses in the first quarter of 2015 comprised of restructuring charges of $406,000. Net loss for the first quarter of 2015 was $9.3 million, or $0.06 per share, contrast to $8.4 million, or $0.06 per share, for the comparable 2014 period. The company ended the first quarter of 2015 with $163.8 million in cash and investments.
Revenues for the first quarter of 2015 and 2014 comprised of royalty and license fee revenues under various agreements. Interest and other income for the first quarter of 2015 was $149,000 contrast to $83,000 for the comparable 2014 period. The enhance in interest and other income in 2015 contrast to 2014 was due to higher cash and investment balances in 2015.
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies.
At the end of Friday’s trade, Galena Biopharma Inc (NASDAQ:GALE)‘s shares dipped -2.90% to $1.34.
Galena Biopharma Inc (GALE) stated its financial results for the quarter ended March 31, 2015 and offered a business update.
FINANCIAL HIGHLIGHTS AND GUIDANCE
Company recognize revenue from the sale of Abstral to wholesale pharmaceutical distributors, net of product-related discounts, allowances, product returns, rebates, chargeback’s, and patient assistance benefits, as applicable. Net revenue was $2.8 million in the first quarter of 2015, a 28% enhance contrast to $2.2 million for the same period a year ago.
Operating loss for the first quarter of 2015 was $11.1 million, counting $0.6 million in stock based compensation, contrast to an operating loss of $11.8 million, counting $1.7 million in stock-based compensation for the same period in 2014. The decrease in net operating loss year-over-year is primarily the result of the completion of enrollment in our Phase 3 PRESENT trial for NeuVax, in addition to the decrease in stock based compensation.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care.
Springleaf Holdings Inc (NYSE:LEAF), ended its Friday’s trading session with -2.83% loss, and closed at $46.76.
Springleaf Holdings Inc (LEAF) stated a GAAP basis net income of $0 million, or $0.00 per diluted share for the first quarter of 2015, contrast with net income of $52 million or $0.45 per diluted share in the first quarter of 2014, which comprised of a pretax gain of $55 million on the sale of real estate assets.
First Quarter Highlights
- Consumer net finance receivables reached $3.9 billion at March 31, 2015, an enhance of $736 million, or 23% from March 31, 2014, and up 2% from December 31, 2014.
- Consumer net finance receivables per branch were $4.7 million at March 31, 2015, up 24% from March 31, 2014 and 2% from December 31, 2014.
- Risk-adjusted yield for our Consumer segment in the quarter was 21.24%, down 68 basis points from the first quarter of 2014.
- The company generated $868 million of total consumer origination volume in the first quarter, counting $207 million of direct auto loan originations. Direct auto loan receivables reached $415 million at quarter-end.
Springleaf Holdings, Inc., through its auxiliaries, offers consumer finance and credit insurance products and services. It provides personal loans secured by consumer household goods, and other personal property; and unsecured loans.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
